Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Optibiotix Health to launch improved version of weight loss product Slimbiome

The new formulation is a single homogenous product, a development that reduces separation in transport
picture of tape measure
New version of Slimbiome will launch in Las Vegas at end of September

OptiBiotix Health plc (LON:OPTI) is to launch an improved version of its hunger suppressant/weight loss product Slimbiome at a major US trade fair at the end of the month.

The new formulation is a single homogenous product, a development that reduces separation in transport and makes it available in places such as in-store bakeries where previously it might have been difficult to blend or remix.

Solubility has also been improved, making it taste and feel better in existing products such as 'GoFigure' shakes and bars.

Improved dispersion in water will help open new markets, said Stephen O’Hara, chief executive as it makes it ideal for gym users who want to mix it into a liquid shake

The new formula will also be cheaper to produce as there is less waste.

Optibiotix already has US product registration for Slimbiome, which is a patented combination of natural ingredients, and will launch the new version at the Supply Side West trade show where it will be exhibited with Cereal Ingredients Inc, a potential joint development partner.

READ: OptiBiotix technology gaining commercial traction; more to come says broker

Cereal Ingredients is considering incorporating SlimBiome into a range of cereal based particulates and ingredients aimed at the nutraceutical, health and wellbeing sectors. 

Other manufacturers are looking at SlimBiome's possible application into 'Health & Wellbeing' food and beverage products.  

READ: OptiBiotix to hook-up with Bened Biomedical to open new routes into south-east Asia for its cholesterol reduction products

Optibiotix is also launching its LPLDL cholesterol and blood pressure lowering product at Supply Side West, which takes place in Las Vegas on 27-28 September. 

O'Hara added: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners.

“As we build the range of applications, products and geographic scope of SlimBiome with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products.”

House broker finncap said the new formula was further evidence of the commercial progress the company is making, with the fact that talks with under way with other potential partners (to add to recent deals with Sacco and Tata Chemical) an encouraging development.

Shares rose 0.5% to 67.9p.

--Adds broker comment, detail and share price--

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use